HOME >> BIOLOGY >> NEWS
From clinical cancer research: rethinking therapeutic cancer vaccine trials

Ongoing therapeutic cancer vaccine trials have yet to show evidence of vaccines spurring a patients immune system to shrink tumors -- yet patients who receive these vaccines in trials tend to live longer and respond better to subsequent treatment. In the July 1 issue of Clinical Cancer Research, a journal of the American Association for Cancer Research, a team of National Cancer Institute researchers asks a fundamental question: are we looking at cancer vaccine trials the wrong way"

In a review of five prostate cancer vaccine trials, NCI researchers offer evidence that patients who receive vaccines may respond better to subsequent chemotherapy or hormone treatment. The specific results or endpoints of these clinical trials, however, were not the long term survival of patients, but rather the degree to which the vaccine caused tumors to shrink. According to the researchers, since they didnt achieve their primary endpoints, these vaccines may be abandoned as dead-ends, despite their real therapeutic value in terms of prolonging patient survival.

Clinical data are providing evidence that patients are living longer following vaccination, de-spite the fact that trials do not show the vaccines can induce the immune system into shrinking tumors, said Jeffrey Schlom, Ph.D., chief of the Laboratory of Tumor Immunology and Biology at the National Cancer Institute. The data suggests that the scientific community and regulatory committees ought to rethink the design of clinical vaccine trials and our current approach to measuring the effectiveness of a cancer vaccine.

According to the researchers, it may be more helpful to think of the effectiveness of a vaccine in terms of the response of the patient, rather than the response of the tumor. While the Response Criteria in Solid Tumors (RECIST) experimental standards works well in evaluating therapies that are toxic to tumors, such as radiation or chemotherapy, they are less capable of me
'"/>

Contact: Greg Lester
lester@aacr.org
267-646-0554
American Association for Cancer Research
3-Jul-2007


Page: 1 2

Related biology news :

1. Preclinical study links gene to brain aneurysm formation
2. Gene variant is associated with brain anatomy, clinical course of ADHD
3. New joint replacement material developed at MGH put to first clinical use
4. Serica scientists win AOSSM Award for ACL (knee) tissue regeneration in preclinical study
5. Manganese levels increase in scrapie-infected sheep before clinical symptoms develop
6. Biovest announces interim blinded data of fast-tracked pivotal Phase 3 clinical trial of BiovaxID
7. Alzheimers drug based on Purdue -- designed inhibitor begins clinical trials
8. UT Southwestern joins national clinical trial to uncover long-term effects of West Nile virus
9. BDSI announces positive phase III clinical trial results
10. Oncolytics Biotech Inc. proceeds to initiate US Phase II sarcoma clinical trial
11. NIH announces phase III clinical trial of creatine for Parkinsons disease

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/5/2019)... ... November 05, 2019 , ... Dr. Lauren Kopp ... dentistry to Seattle, WA, including porcelain veneers , smile makeovers, dental implants, ... University of Washington, Dr. Kopp is passionate about serving her Seattle community with ...
(Date:11/2/2019)... ... 2019 , ... Stay on top of current hot topics through free webinars ... webinars is free, so be sure to register today to save your place! Participate ... to see our upcoming webinars: , CLINICAL OPERATIONS , November 14 – Leveraging Technology ...
(Date:10/30/2019)... ... October 30, 2019 , ... The ... Knowledge Center in which participants will learn about precision agriculture tools used to ... these technologies. , Participants will have the opportunity to visit Virginia Tech’s ...
Breaking Biology News(10 mins):
(Date:11/9/2019)... , ... November 08, 2019 ... ... artificial intelligence (AI)-powered technology for use in pathology research, today announced the ... biopsy samples from patients enrolled in the phase 3 selonsertib studies (STELLAR). ...
(Date:11/6/2019)... , ... November 06, 2019 , ... ... through off-the-record collaboration and dialogue, today announces its East/West CEO conference ... in San Francisco. , Kicking off the week of the J.P. ...
(Date:11/5/2019)... ... 2019 , ... Focal Healthcare , an innovator of ... Bx 2.0 prostate fusion biopsy solution. By combining information from multiparametric MRI (mpMRI) ... urologists across Europe the ability to perform targeted transrectal and transperineal prostate biopsies. ...
(Date:11/2/2019)... ... October 31, 2019 , ... A ... communicating with each other: study managers, principal investigators, supply chain managers, manufacturers, IRT, ... is not informed of the latest data, potentially leading to patient risk. , ...
Breaking Biology Technology:
Cached News: